PKD1 and cyst: The other piece of evidence is that cells carrying mutations in PKD1 or PKD2 show greatly enhanced sensitivity to cAMP elevation, showing more cysts than wild-type controls at the same concentration of cAMP-elevating drug, and requiring lower concentrations of these drugs to begin cyst formation at all.